2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| ELI LILLY & Co | — | 6,344,114 | Jan 15, 2026 |
| Gadicke Ansbert | 10% Owner | 341,709 | Jan 8, 2026 |
| Mpm Asset Management Llc | 10% Owner | 341,709 | Jan 8, 2026 |
| Oncology Impact Private Investment Fund 2, L.P. | 10% Owner | 341,709 | Jan 8, 2026 |
| Evnin Luke | 10% Owner | 341,709 | Jan 8, 2026 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | ELI LILLY & Co | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 12, 2026 | Jan 14, 2026 | Foley Todd | Director | Buy | 95.0 | +232,870 | 5.82% | ✗ | $4.2M |
| Jan 12, 2026 | Jan 14, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | Buy | 100.0 | +1,112,777 | 12.17% | ✗ | $20M |
| Jan 12, 2026 | Jan 14, 2026 | GADICKE ANSBERT | 10% Owner | Buy | 100.0 | +1,112,777 | 12.17% | ✗ | $20M |
| Jan 12, 2026 | Jan 12, 2026 | EcoR1 Capital, LLC | Director | Buy | 100.0 | +2,222,222 | 89.83% | ✗ | $40M |
| Jan 12, 2026 | Jan 12, 2026 | Vida Ventures II, LLC | 10% Owner | Buy | 100.0 | +835,000 | 16.72% | ✗ | $15M |
| Jan 12, 2026 | Jan 12, 2026 | Kim Helen Susan | Director | Buy | 100.0 | +835,000 | 16.72% | ✗ | $15M |
| Jan 12, 2026 | Jan 12, 2026 | Segal Lloyd Mitchell | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 8, 2026 | Kuvalanka Kyle D. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Kim Helen Susan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Herrmann Ken | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | GADICKE ANSBERT | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Segal Lloyd Mitchell | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | RODEN MATTHEW | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Ron-Bigger Shulamit | COO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Foley Todd | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Feldman Paul L | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Czibere Akos | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Sherman Michael A. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Thistle Mary | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | EcoR1 Capital, LLC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 8, 2026 | Vida Ventures II, LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - |